Mark Boyd

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. ncbi request reprint Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?
    Mark Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, NSW, Australia
    Expert Opin Pharmacother 8:957-64. 2007
  2. doi request reprint Current and future management of treatment failure in low- and middle-income countries
    Mark A Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Curr Opin HIV AIDS 5:83-9. 2010
  3. ncbi request reprint A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)
    Mark A Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    Antivir Ther 13:449-53. 2008
  4. ncbi request reprint Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research
    Mark A Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    AIDS 21:S55-63. 2007
  5. pmc Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy
    Hamish McManus
    The Kirby Institute, UNSW, Sydney, New South Wales, Australia
    PLoS ONE 7:e48839. 2012
  6. doi request reprint Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 24:2657-63. 2010
  7. doi request reprint Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials
    Dianne Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney 2052, New South Wales, Australia
    J Antimicrob Chemother 65:1878-88. 2010
  8. ncbi request reprint Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens
    Stephen J Kerr
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Int Assoc Physicians AIDS Care (Chic) 6:36-46. 2007
  9. doi request reprint Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression
    Helen Byakwaga
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    AIDS Res Hum Retroviruses 25:756-76. 2009
  10. ncbi request reprint Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort
    W Phillip Law
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, Sydney, Australia
    AIDS 18:1169-77. 2004

Detail Information

Publications22

  1. ncbi request reprint Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?
    Mark Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, NSW, Australia
    Expert Opin Pharmacother 8:957-64. 2007
    ..i.d., retains potency and is considerably less toxic. As a result, there is interest in its application in resource-constrained settings...
  2. doi request reprint Current and future management of treatment failure in low- and middle-income countries
    Mark A Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Curr Opin HIV AIDS 5:83-9. 2010
    ..This paper aims to describe and review access to second-line therapy in low- and middle-income countries at present and examine future possibilities...
  3. ncbi request reprint A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)
    Mark A Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    Antivir Ther 13:449-53. 2008
    ..The antiretroviral enfuvirtide (ENF) is injected subcutaneously using a 27-gauge needle. Injection site reactions (ISRs) can affect long-term ENF tolerability. Alternative ENF delivery methods may ameliorate ISRs...
  4. ncbi request reprint Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research
    Mark A Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    AIDS 21:S55-63. 2007
    ..Therefore, the funding bodies responsible for the roll-out of antiretroviral access across the globe must mandate, incorporate and fund clinical research as an intrinsic aspect of combination ART roll-out programmes...
  5. pmc Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy
    Hamish McManus
    The Kirby Institute, UNSW, Sydney, New South Wales, Australia
    PLoS ONE 7:e48839. 2012
    ..We examined long-term survival in HIV-positive patients receiving cART in the Australian HIV Observational Database (AHOD), to describe changes in mortality compared to the general population and to develop longer-term survival models...
  6. doi request reprint Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 24:2657-63. 2010
    ..7, P = 0.048) in ABC/3TC recipients compared with TDF/FTC in the STEAL study. The impact of ABC/3TC treatment on a range of CVD and inflammatory biomarkers was explored...
  7. doi request reprint Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials
    Dianne Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney 2052, New South Wales, Australia
    J Antimicrob Chemother 65:1878-88. 2010
    ..To compare lipid profiles in HIV-infected adults receiving atazanavir-based regimens...
  8. ncbi request reprint Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens
    Stephen J Kerr
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Int Assoc Physicians AIDS Care (Chic) 6:36-46. 2007
    ..Non-stavudine-containing non-boosted protease-inhibitor-based highly active antiretroviral treatment regimens had the least association with dyslipidemia...
  9. doi request reprint Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression
    Helen Byakwaga
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    AIDS Res Hum Retroviruses 25:756-76. 2009
    ..Our results point to an advantage to commencing ART at higher CD4+ T cell strata. These data should be considered when estimating the optimal time to initiate ART...
  10. ncbi request reprint Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort
    W Phillip Law
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, Sydney, Australia
    AIDS 18:1169-77. 2004
    ..To examine the impact of viral hepatitis co-infection on HIV disease outcomes following commencement of combination antiretroviral therapy in a developing country setting...
  11. doi request reprint Improvements in antiretroviral therapy outcomes over calendar time
    Mark A Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    Curr Opin HIV AIDS 4:194-9. 2009
    ..It is in turn assumed that these developments have led to improved outcomes in the latter era of cART...
  12. ncbi request reprint Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001
    W Phillip Law
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 17:2191-9. 2003
    ..To examine rates and predictors of severe hepatotoxicity with combination antiretroviral therapy in a developing country setting: the eight HIV-NAT randomized controlled trials in Thailand...
  13. ncbi request reprint The Sydney Declaration: a call to scale up research
    David Cooper
    University of New South Wales, Sydney, NSW, Australia
    Lancet 370:7-8. 2007
  14. ncbi request reprint Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 34:134-9. 2003
    ....
  15. ncbi request reprint Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen
    Reshma S Autar
    The HIV Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Antivir Ther 12:1265-71. 2007
    ..The pathogenesis of metabolic disturbances in treated HIV infection is incompletely understood...
  16. ncbi request reprint Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis
    Mark A Boyd
    AIDS 20:1083-5. 2006
  17. ncbi request reprint The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity
    Mark A Boyd
    HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre Bangkok, Thailand
    J Antimicrob Chemother 57:1161-7. 2006
    ..We prospectively studied the use of therapeutic drug monitoring in patients with virological success but established nephrotoxicity on an indinavir-containing regimen...
  18. ncbi request reprint Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012)
    Mark A Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Infect Dis 194:1319-22. 2006
    ..62+/-0.34 per day and -0.51+/-0.16 per day; P>.1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor...
  19. ncbi request reprint Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz
    Mark A Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Infect Dis 194:642-50. 2006
    ..Improvements in lipoatrophy after a switch in nucleoside reverse-transcriptase inhibitors (NRTIs) have been demonstrated. We investigated 60 patients switching from failed NRTIs to ritonavir-boosted indinavir and efavirenz...
  20. ncbi request reprint Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Antivir Ther 11:223-32. 2006
    ..The use of HIV protease inhibitors (PIs) in a ritonavir (RTV)-boosted form is now common. However, randomized data comparing boosted with unboosted PI strategies are scarce...
  21. ncbi request reprint Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Pharmacogenet Genomics 16:321-9. 2006
    ..To investigate the association between the UGT1A1*6 (G71R) and UGT1A1*28 (promoter (TA)7-repeat) genotypes and hyperbilirubinaemia in Thai patients treated with indinavir, and characterize the inhibition of human UGTs by indinavir in vitro...
  22. ncbi request reprint Creation of a drug fund for post-clinical trial access to antiretrovirals
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Pathumwan, Bangkok 10330, Thailand
    Lancet 364:101-2. 2004